HEMGENIX®

Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial

Gene therapy with etranacogene dezaparvovec for hemophilia B

Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy

Stable Factor IX Expression and Sustained Reductions in Factor IX Use 8 Years After

View Poster

Please see full prescribing information for HEMGENIX

Four-year results of etranacogene dezaparvovec in haemophilia B patients with pre-existing AAV5 neutralising antibodies: Phase 3 HOPE-B trial

View Poster

Please see full prescribing information for HEMGENIX

Four-year results of etranacogene dezaparvovec in haemophilia B patients without pre-existing AAV5 neutralising antibodies: Phase 3 HOPE-B trial

View Poster

Please see full prescribing information for HEMGENIX

Natural history of AAV5 neutralising antibodies in adults with haemophilia B during ≥6-month screening and lead-in to the HOPE-B trial with etranacogene dezaparvovec gene therapy

View Poster

Please see full prescribing information for HEMGENIX

Etranacogene dezaparvovec-drlb hemophilia B gene therapy Phase 2b trial final results: Stable and durable FIX level expression over 5 years

View Poster

Please see full prescribing information for HEMGENIX

IX-TEND: A Phase IV Observational, Long-term Follow-up Study on the Safety and Efficacy of Etranacogene Dezaparvovec in Patients with Hemophilia B

View Poster

Please see full prescribing information for HEMGENIX

First Real-world Experience Administering Etranacogene Dezaparvovec Gene Therapy for People with Hemophilia B

View Poster

Please see full prescribing information for HEMGENIX

Sustained efficacy and safety 3 years following infusion with etranacogene dezaparvovec in adults with severe or moderately severe hemophilia B in the Phase 3 HOPE-B clinical trial

View Poster

Please see full prescribing information for HEMGENIX

HIV Comorbid Infection and Liver-Directed AAV-Based Gene Therapy in Adults with Severe and Moderately Severe Hemophilia B: Efficacy and Safety Results from Phase 2b and the Pivotal Phase 3 HOPE-B Trials 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec

View Poster

Please see full prescribing information for HEMGENIX

Adult Patients With Hemophilia B and With a History of Chronic HCV/HBV Infection Receiving Liver Directed Gene Therapy Demonstrated Long-Term Bleeding Protection And Sustained FIX Activity: Efficacy and Safety Results 3 Years After Administration of a Single Dose of Etranacogene Dezaparvovec

View Poster

Please see full prescribing information for HEMGENIX

Management of Infusion Reactions: Lessons from the Phase 3 HOPE-B Gene Therapy Trial of Etranacogene Dezaparvovec in Adults with Hemophilia B 

View Poster

Please see full prescribing information for HEMGENIX

Improvements in health-related quality of life in adults with severe or moderately severe hemophilia B after receiving etranacogene dezaparvovec gene therapy

View Poster

Please see full prescribing information for HEMGENIX

Analysis of elevated alanine transaminase in HOPE B, a Phase 3 recombinant adeno associated viral 5 gene therapy trial in people with haemophilia B

View Poster

Please see full prescribing information for HEMGENIX